HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nu Skin

This article was originally published in The Rose Sheet

Executive Summary

Weaker than expected results in the U.S., mainland China and Japan in the third quarter have prompted the company to lower revenue expectations, projecting sales will be up 2% to $290 mil., versus earlier estimates of $298 mil.-$303 mil., Nu Skin reports Oct. 4. Earnings per share during the quarter will be in the range of $.24-$.26, compared to earlier projections of $.29-$.30. Based on Q3 expectations, Nu Skin is revising its fourth quarter revenue guidance to $300 mil.-$306 mil., "assuming an exchange rate of 112 yen to the dollar, which would result in annual revenue increasing 5% to approximately $1.2 bil. for 2005," firm adds...

You may also be interested in...

Nu Skin

Business "simplification" initiative in 2006 intended to benefit direct-seller's sales force will result in $15 mil.-$25 mil. in restructuring charges to be taken within the next few quarters, Nu Skin announces Nov. 30. As part of its strategy, company plans to "eliminate organizational redundancies, revamp administrative support functions, prioritize investments to favor profitable initiatives and markets, and increase efficiencies in our supply chain process." In addition to revenue shortfall, charges also will cause negative impact on earnings per share, firm notes. Strength of U.S. dollar against other currencies also has led company to revise fourth quarter sales estimates to $285 mil.-$290 mil. versus prior expectations of $300 mil.-$305 mil. (1"The Rose Sheet" Oct. 10, 2005, In Brief). Decline in revenue is anticipated to reduce earnings per share in Q4 by about $.03, firm adds...

Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement

The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts